Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERMAID1 anti-CD19 CAR T in adult B-ALL
2024-519808-27-00Phase 2Suspended
- Sponsor
- Medical University of Warsaw
- Start
- Jan 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tarcidomgen kimleucel in acute lymphoblastic leukemia (ALL), sponsored by Medical University of Warsaw. Primary endpoints: Overall response rate (ORR) and Treatment-emergent adverse events of special interest (Grade ≥ 3). Started Jan 2025; status: suspended.
02
Drugs
tarcidomgen kimleucel
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2024-519808-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519808-27-00.